Disfunction of the apoptotic pathway in cancer cells

Application of Apoptosis to Cancer Treatment

Volumn , Issue , 2005, Pages 1-28

  Yang, Lily ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis resistance; apoptosis signal defects; apoptotic signal pathway; human cancer cell

Indexed keywords

EID: 80054699437     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/1-4020-3302-8_1     Document Type: Chapter

References (208)

1. Wyllie AH. Apoptosis: cell death under homeostatic control. Arch Toxicol Suppl 1987; 11: 3-10.
2. Rich T, Allen RL, Wyllie AH. Defying death after DNA damage. Nature 2000; 407: 777-783.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
4. Hickman ES, Helin K. The regulation of APAF1 expression during development and tumourigenesis. Apoptosis 2002; 7: 167-171.
5. Wyllie AH et al. Apoptosis and carcinogenesis. Br J Cancer 1999; 80 Suppl 1: 34-37.
6. Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 1999; 11: 68-75.
7. Holcik M, Gibson H, Korneluk RG. XIAP: apoptotic brake and promising therapeutic target. Apoptosis 2001; 6: 253-261.
8. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002; 2: 277-288.
9. Altieri DC. Survivin and apoptosis control. Adv Cancer Res 2003; 88: 31-52.
10. Zakeri Z, Lockshin RA. Cell death during development. J Immunol Methods 2002; 265: 3-20.
11. Spencer SJ, Cataldo NA, Jaffe RB. Apoptosis in the human female reproductive tract. Obstet Gynecol Surv 1996; 51: 314-323.
12. Debnath J et al. The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 2002; 111: 29-40.
13. Hahm HaD, NE. Apoptosis in the mammary gland and breast cancer. Endocrine-Related Cancer 1998; 5: 199-211.
14. Collins M. Potential roles of apoptosis in viral pathogenesis. Am J Respir Crit Care Med 1995; 152: S20-24.
15. Winoto A. Cell death in the regulation of immune responses. Curr Opin Immunol 1997; 9: 365-370.
16. Kamarajan P, Chao CC. UV-induced apoptosis in resistant HeLa cells. Biosci Rep 2000; 20: 99-108.
17. Park IC et al. Ionizing radiation and nitric oxide donor sensitize Fas-induced apoptosis via up-regulation of Fas in human cervical cancer cells. Oncol Rep 2003; 10: 629-633.
18. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000; 256: 42-49.
19. Reed JC. Mechanisms of apoptosis. Am J Pathol 2000; 157: 1415-1430.
20. Suzuki A et al. Mitochondrial regulation of cell death: mitochondria are essential for procaspase 3-p21 complex formation to resist Fas-mediated cell death. Mol Cell Biol 1999; 19: 3842-3847.
21. Henry-Mowatt J, Dive C, Martinou JC, James D. Role of mitochondrial membrane permeabilization in apoptosis and cancer. Oncogene 2004; 23: 2850-2860.
22. Budihardjo I et al. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999; 15: 269-290.
23. Stroh C, Schulze-Osthoff K. Death by a thousand cuts: an ever increasing list of caspase substrates. Cell Death Differ 1998; 5: 997-1000.
24. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003; 10: 26-35.
25. Barnhart BC et al. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. Embo J 2004; 23: 3175-3185.
26. Landowski TH et al. CD95 antigen mutations in hematopoietic malignancies. Leuk Lymphoma 2001; 42: 835-846.
27. Beltinger C et al. CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood 1998; 91: 3943-3951.
28. Lee SH et al. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene 1999; 18: 3754-3760.
29. Boldrini L et al. Identification of Fas (APO-1/CD95) and p53 gene mutations in non-small cell lung cancer. Int J Oncol 2002; 20: 155-159.
30. Bullani RR et al. Frequent downregulation of Fas (CD95) expression and function in melanoma. Melanoma Res 2002; 12: 263-270.
31. Lee SH et al. Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. Hum Pathol 2001; 32: 250-256.
32. Nambu Y et al. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. J Clin Invest 1998; 101: 1102-1110.
33. Viard-Leveugle I et al. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma. J Pathol 2003; 201: 268-277.
34. Lee SH et al. In vivo expression of soluble Fas and FAP-1: possible mechanisms of Fas resistance in human hepatoblastomas. J Pathol 1999; 188: 207-212.
35. Liu JH et al. Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia. Blood 2002; 100: 1449-1453.
36. Elnemr A et al. Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway. Int J Oncol 2001; 18: 311-316.
37. Gerharz CD et al. Resistance to CD95 (APO-1/Fas)-mediated apoptosis in human renal cell carcinomas: an important factor for evasion from negative growth control. Lab Invest 1999; 79: 1521-1534.
38. Muschen M et al. Resistance to CD95-mediated apoptosis in breast cancer is not due to somatic mutation of the CD95 gene. Int J Cancer 2001; 92: 309-310.
39. Keane MM et al. Fas expression and function in normal and malignant breast cell lines. Cancer Res 1996; 56: 4791-4798.
40. Ungefroren H et al. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 1998; 58: 1741-1749.
41. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-1178.
42. Bellgrau D et al. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630-632.
43. Mullauer L et al. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer. J Pathol 2000; 190: 20-30.
44. Abrahams VM, Kamsteeg M, Mor G. The Fas/Fas ligand system and cancer: immune privilege and apoptosis. Mol Biotechnol 2003; 25: 19-30.
45. Bennett MW et al. Fas ligand upregulation is an early event in colonic carcinogenesis. J Clin Pathol 2001; 54: 598-604.
46. Herrnring C et al. Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors. Histochem Cell Biol 2000; 113: 189-194.
47. Sheehan KM et al. Prognostic relevance of Fas (APO-1/CD95) ligand in human colorectal cancer. Eur J Gastroenterol Hepatol 2003; 15: 375-380.
48. Boesen-de Cock JG et al. Common regulation of apoptosis signaling induced by CD95 and the DNA-damaging stimuli etoposide and gamma-radiation downstream from caspase-8 activation. J Biol Chem 1999; 274: 14255-14261.
49. Fulda S et al. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997; 57: 3823-3829.
50. Landowski TH, Gleason-Guzman MC, Dalton WS. Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood 1997; 89: 1854-1861.
51. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003; 22: 8628-8633.
52. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004; 4: 333-339.
53. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003; 10: 66-75.
54. Marsters SA, Pitti RA, Sheridan JP, Ashkenazi A. Control of apoptosis signaling by Apo2 ligand. Recent Prog Horm Res 1999; 54: 225-234.
55. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999; 11: 255-260.
56. Ibrahim SM et al. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas 2001; 23: 72-79.
57. Singh TR et al. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 2003; 63: 5390-5400.
58. Jin Z, McDonald ER, 3rd, Dicker DT, El-Deiry WS. Deficient TRAIL death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem 2004.
59. Odoux C et al. TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer. Int J Cancer 2002; 97: 458-465.
60. Shankar S, Srivastava RK. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat 2004; 7: 139-156.
61. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-1308.
62. Morgan M, Thorburn J, Pandolfi PP, Thorburn A. Nuclear and cytoplasmic shuttling of TRADD induces apoptosis via different mechanisms. J Cell Biol 2002; 157: 975-984.
63. Varfolomeev EE, Ashkenazi A. Tumor necrosis factor: an apoptosis JuNKie? Cell 2004; 116: 491-497.
64. Micheau O et al. NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol 2001; 21: 5299-5305.
65. Murray PG et al. Expression of the tumour necrosis factor receptor-associated factors 1 and 2 in Hodgkin's disease. J Pathol 2001; 194: 158-164.
66. Zapata JM et al. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol 2000; 165: 5084-5096.
67. Hopkins-Donaldson S et al. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ 2003; 10: 356-364.
68. Iolascon A et al. Caspase 3 and 8 deficiency in human neuroblastoma. Cancer Genet Cytogenet 2003; 146: 41-47.
69. Teitz T et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000; 6: 529-535.
70. Fujikawa K et al. Reduced expression of ICE/caspase1 and CPP32/caspase3 in human hepatocellular carcinoma. Anticancer Res 2000; 20: 1927-1932.
71. Kolenko V et al. Dead or dying: necrosis versus apoptosis in caspase-deficient human renal cell carcinoma. Cancer Res 1999; 59: 2838-2842.
72. Palmerini F et al. Caspase 7 downregulation as an immunohistochemical marker of colonic carcinoma. Hum Pathol 2001; 32: 461-467.
73. Chu ZL et al. A novel enhancer of the Apaf1 apoptosome involved in cytochrome c-dependent caspase activation and apoptosis. J Biol Chem 2001; 276: 9239-9245.
74. Soengas MS et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001; 409: 207-211.
75. Nakopoulou L et al. Immunohistochemical expression of caspase-3 as an adverse indicator of the clinical outcome in human breast cancer. Pathobiology 2001; 69: 266-273.
76. Vakkala M, Paakko P, Soini Y. Expression of caspases 3, 6 and 8 is increased in parallel with apoptosis and histological aggressiveness of the breast lesion. Br J Cancer 1999; 81: 592-599.
77. Parton M et al. Coordinate Expression of Apoptosis-associated Proteins in Human Breast Cancer before and during Chemotherapy. Clin Cancer Res 2002; 8: 2100-2108.
78. O'Donovan N et al. Caspase 3 in breast cancer. Clin Cancer Res 2003; 9: 738-742.
79. Yang L, Cao Z, Yan H, Wood WC. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res 2003; 63: 6815-6824.
80. Satoh K et al. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 2001; 92: 271-278.
81. Yoo NJ et al. Stomach cancer highly expresses both initiator and effector caspases; an immunohistochemical study. Apmis 2002; 110: 825-832.
82. Kennedy NJ, Kataoka T, Tschopp J, Budd RC. Caspase activation is required for T cell proliferation. J Exp Med 1999; 190: 1891-1896.
83. Mouhamad S et al. Differential modulation of interleukin-2-and interleukin-4-mediated early activation of normal human B lymphocytes by the caspase inhibitor zVAD-fmk. Eur Cytokine Netw 2002; 13: 439-445.
84. Rendl M et al. Caspase-14 expression by epidermal keratinocytes is regulated by retinoids in a differentiation-associated manner. J Invest Dermatol 2002; 119: 1150-1155.
85. Reichmann E. The biological role of the Fas/FasL system during tumor formation and progression. Semin Cancer Biol 2002; 12: 309-315.
86. Scaffidi C, Schmitz I, Krammer PH, Peter ME. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 1999; 274: 1541-1548.
87. Abedini MR, Qiu Q, Yan X, Tsang BK. Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene 2004.
88. Lee SH et al. Increased expression of FLIP, an inhibitor of Fas-mediated apoptosis, in stomach cancer. Apmis 2003; 111: 309-314.
89. Griffith TS et al. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998; 161: 2833-2840.
90. Kamarajan P, Sun NK, Chao CC. Up-regulation of FLIP in cisplatin-selected HeLa cells causes cross-resistance to CD95/Fas death signalling. Biochem J 2003; 376: 253-260.
91. Reed JC. Bcl-2 family proteins. Oncogene 1998; 17: 3225-3236.
92. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003; 22: 8590-8607.
93. Reed JC. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 1995; 9: 451-473.
94. Gee JM et al. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 1994; 59: 619-628.
95. Tu Y et al. Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood 1996; 88: 1805-1812.
96. Fulda S, Meyer E, Debatin KM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002; 21: 2283-2294.
97. Wang S, Yang D, Lippman ME. Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol 2003; 30: 133-142.
98. Reed JC. Promise and problems of Bcl-2 antisense therapy. J Natl Cancer Inst 1997; 89: 988-990.
99. Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov 2002; 1: 111-121.
100. Krajewski S et al. Prognostic significance of apoptosis regulators in breast cancer. Endocr Relat Cancer 1999; 6: 29-40.
101. Feuerhake F et al. Immunohistochemical analysis of Bcl-2 and Bax expression in relation to cell turnover and epithelial differentiation markers in the non-lactating human mammary gland epithelium. Cell Tissue Res 2000; 299: 47-58.
102. Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994; 145: 1191-1198.
103. Zhang GJ et al. Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers. Anticancer Res 1998; 18: 1989-1998.
104. Villar E et al. bcl-2 Expression and apoptosis in primary and metastatic breast carcinomas. Tumour Biol 2001; 22: 137-145.
105. Gutierrez MI et al. Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis. Cancer Res 1999; 59: 696-703.
106. Knudson CM, Johnson GM, Lin Y, Korsmeyer SJ. Bax accelerates tumorigenesis in p53-deficient mice. Cancer Res 2001; 61: 659-665.
107. Rampino N et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997; 275: 967-969.
108. Bargou RC et al. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 1995; 60: 854-859.
109. Krajewski S et al. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995; 55: 4471-4478.
110. Redondo M et al. Expression of bax and p53 proteins in the tumorigenesis and progression of breast carcinomas. Tumour Biol 2003; 24: 23-31.
111. Roy N et al. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. Embo J 1997; 16: 6914-6925.
112. Suzuki Y et al. X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and-7 in distinct modes. J Biol Chem 2001; 276: 27058-27063.
113. Kasof GM, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 2001; 276: 3238-3246.
114. Zhang HG et al. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 2004; 23: 2009-2015.
115. Tamm I et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998; 58: 5315-5320.
116. Dohi T et al. An IAP-IAP complex inhibits apoptosis. J Biol Chem 2004; 279: 34087-34090.
117. Du C et al. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33-42.
118. Liu Z et al. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 2000; 408: 1004-1008.
119. Liston P et al. Identification of XAF1 as an antagonist of XIAP anti-Caspase activity. Nat Cell Biol 2001; 3: 128-133.
120. Fong WG et al. Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. Genomics 2000; 70: 113-122.
121. Byun DS et al. Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res 2003; 63: 7068-7075.
122. Adida C et al. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 1998; 152: 43-49.
123. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22: 8581-8589.
124. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921.
125. Li F. Survivin study: what is the next wave? J Cell Physiol 2003; 197: 8-29.
126. Tanaka K et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000; 6: 127-134.
127. Sarela AI et al. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer 2002; 86: 886-892.
128. Islam A et al. Role of survivin, whose gene is mapped to 17q25, in human neuroblastoma and identification of a novel dominant-negative isoform, survivin-beta/2B. Med Pediatr Oncol 2000; 35: 550-553.
129. Hattori M, Sakamoto H, Satoh K, Yamamoto T. DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. Cancer Lett 2001; 169: 155-164.
130. Bao R et al. Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst 2002; 94: 522-528.
131. Hoffman WH et al. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277: 3247-3257.
132. Asanuma K et al. A role for survivin in radioresistance of pancreatic cancer cells. Jpn J Cancer Res 2002; 93: 1057-1062.
133. Kawasaki H et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998; 58: 5071-5074.
134. Kami K et al. Survivin expression is a prognostic marker in pancreatic cancer patients. Surgery 2004; 136: 443-448.
135. Grossman D et al. Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest 2001; 108: 991-999.
136. Mesri M et al. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 2001; 108: 981-990.
137. Zangemeister-Wittke U. Antisense to apoptosis inhibitors facilitates chemotherapy and TRAIL-induced death signaling. Ann N Y Acad Sci 2003; 1002: 90-94.
138. Li F et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999; 1: 461-466.
139. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70: 523-526.
140. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-310.
141. Polyak K et al. A model for p53-induced apoptosis. Nature 1997; 389: 300-305.
142. Muller M et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998; 188: 2033-2045.
143. Yin C, Knudson CM, Korsmeyer SJ, Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 1997; 385: 637-640.
144. Yu J et al. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci USA 2003; 100: 1931-1936.
145. Marchenko ND, Zaika A, Moll UM. Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem 2000; 275: 16202-16212.
146. Mihara M et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003; 11: 577-590.
147. Danielsen AJ, Maihle NJ. The EGF/ErbB receptor family and apoptosis. Growth Factors 2002; 20: 1-15.
148. Ram TG, Ethier SP. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. Cell Growth Differ 1996; 7: 551-561.
149. Toker A, Newton AC. Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J Biol Chem 2000; 275: 8271-8274.
150. Datta SR et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-241.
151. Sabbatini P, McCormick F. Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53-mediated, transcriptionally dependent apoptosis. J Biol Chem 1999; 274: 24263-24269.
152. Dan HC et al. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 2004; 279: 5405-5412.
153. Tran J et al. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 1999; 264: 781-788.
154. Fry MJ. Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play? Breast Cancer Res 2001; 3: 304-312.
155. Hutchinson J et al. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 2001; 21: 2203-2212.
156. O'Gorman DM, McKenna SL, McGahon AJ, Cotter TG. Inhibition of PI3-kinase sensitises HL60 human leukaemia cells to both chemotherapeutic drug-and Fas-induced apoptosis by a JNK independent pathway. Leuk Res 2001; 25: 801-811.
157. Haas-Kogan D et al. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 1998; 8: 1195-1198.
158. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000; 18: 621-663.
159. Kimura K, Gelmann EP. Propapoptotic effects of NF-kappaB in LNCaP prostate cancer cells lead to serine protease activation. Cell Death Differ 2002; 9: 972-980.
160. Dudley E et al. NF-kappaB regulates Fas/APO-1/CD95-and TCR-mediated apoptosis of T lymphocytes. Eur J Immunol 1999; 29: 878-886.
161. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301-310.
162. Kucharczak J, Simmons MJ, Fan Y, Gelinas C. To be, or not to be: NF-kappaB is the answer-role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 2003; 22: 8961-8982.
163. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003; 114: 181-190.
164. Grumont RJ, Rourke IJ, Gerondakis S. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev 1999; 13: 400-411.
165. Viatour P et al. NF-kappa B2/p100 induces Bcl-2 expression. Leukemia 2003; 17: 1349-1356.
166. Notarbartolo M et al. Expression of the IAPs in multidrug resistant tumor cells. Oncol Rep 2004; 11: 133-136.
167. Wang Q, Wang X, Evers BM. Induction of cIAP-2 in human colon cancer cells through PKC delta/NF-kappa B. J Biol Chem 2003; 278: 51091-51099.
168. Harwood FG et al. Regulation of FasL by NF-kappaB and AP-1 in Fas-dependent thymineless death of human colon carcinoma cells. J Biol Chem 2000; 275: 10023-10029.
169. Lin A, Karin M. NF-kappaB in cancer: a marked target. Semin Cancer Biol 2003; 13: 107-114.
170. Cao Y, Karin M. NF-kappaB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 2003; 8: 215-223.
171. Eid MA, Lewis RW, Abdel-Mageed AB, Kumar MV. Reduced response of prostate cancer cells to TRAIL is modulated by NFkappaB-mediated inhibition of caspases and Bid activation. Int J Oncol 2002; 21: 111-117.
172. Meli M et al. NF-kappaB inhibition restores sensitivity to Fas-mediated apoptosis in lymphoma cell lines. Ann N Y Acad Sci 2003; 1010: 232-236.
173. Semenza GL. Involvement of hypoxia-inducible factor 1 in human cancer. Intern Med 2002; 41: 79-83.
174. Shibaji T et al. Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer. Anticancer Res 2003; 23: 4721-4727.
175. Akakura N et al. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 2001; 61: 6548-6554.
176. Bardos JI, Ashcroft M. Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays 2004; 26: 262-269.
177. Weinmann M, Belka C, Plasswilm L. Tumour hypoxia: impact on biology, prognosis and treatment of solid malignant tumours. Onkologie 2004; 27: 83-90.
178. Piret JP, Mottet D, Raes M, Michiels C. Is HIF-1alpha a pro-or an anti-apoptotic protein? Biochem Pharmacol 2002; 64: 889-892.
179. Weinmann M et al. Molecular ordering of hypoxia-induced apoptosis: critical involvement of the mitochondrial death pathway in a FADD/caspase-8 independent manner. Oncogene 2004; 23: 3757-3769.
180. Piret JP et al. Hypoxia and CoCl2 protect HepG2 cells against serum deprivation-and t-BHP-induced apoptosis: a possible anti-apoptotic role for HIF-1. Exp Cell Res 2004; 295: 340-349.
181. Dong Z, Wang JZ, Yu F, Venkatachalam MA. Apoptosis-resistance of hypoxic cells: multiple factors involved and a role for IAP-2. Am J Pathol 2003; 163: 663-671.
182. Dong Z, Wang J. Hypoxia selection of death-resistant cells. A role for Bcl-X(L). J Biol Chem 2004; 279: 9215-9221.
183. Yokoi K, Fidler IJ. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res 2004; 10: 2299-2306.
184. Yang L et al. Tumor-specific gene expression using the survivin promoter is further increased by hypoxia. Gene Ther 2004; 11: 1215-1223.
185. Sowter HM et al. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res 2001; 61: 6669-6673.
186. Okami J, Simeone DM, Logsdon CD. Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer. Cancer Res 2004; 64: 5338-5346.
187. An WG et al. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 1998; 392: 405-408.
188. Mitsiades N, Poulaki V, Mitsiades CS, Anderson KC. Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug. Expert Opin Investig Drugs 2001; 10: 1075-1084.
189. Sethi T et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999; 5: 662-668.
190. Valentijn AJ, Zouq N, Gilmore AP. Anoikis. Biochem Soc Trans 2004; 32: 421-425.
191. Hojilla CV, Mohammed FF, Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 2003; 89: 1817-1821.
192. Duffy MJ et al. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000; 2: 252-257.
193. Strand S et al. Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells. Oncogene 2004; 23: 3732-3736.
194. Mitsiades N et al. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 2001; 61: 577-581.
195. Vargo-Gogola T, Fingleton B, Crawford HC, Matrisian LM. Matrilysin (matrix metalloproteinase-7) selects for apoptosis-resistant mammary cells in vivo. Cancer Res 2002; 62: 5559-5563.
196. Aoudjit F, Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 2001; 20: 4995-5004.
197. Jan Y et al. A mitochondrial protein, Bit1, mediates apoptosis regulated by integrins and Groucho/TLE corepressors. Cell 2004; 116: 751-762.
198. Ambar BB et al. Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand. Hum Gene Ther 1999; 10: 1641-1648.
199. Komata T et al. Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells. Hum Gene Ther 2002; 13: 1015-1025.
200. Shinoura N et al. Transduction of Apaf-1 or caspase-9 induces apoptosis in A-172 cells that are resistant to p53-mediated apoptosis. Biochem Biophys Res Commun 2000; 272: 667-673.
201. Shinoura N et al. Adenovirus-mediated transfer of caspase-3 with Fas ligand induces drastic apoptosis in U-373MG glioma cells. Exp Cell Res 2000; 256: 423-433.
202. Li X et al. Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer. Cancer Res 2001; 61: 186-191.
203. Pataer A et al. Adenovirus-mediated Bak gene transfer induces apoptosis in mesothelioma cell lines. J Thorac Cardiovasc Surg 2001; 121: 61-67.
204. Park WS et al. Somatic mutations in the death domain of the Fas (Apo-1/CD95) gene in gastric cancer. J Pathol 2001; 193: 162-168.
205. Schimmer AD et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004; 5: 25-35.
206. Grossman D, Kim PJ, Schechner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 2001; 98: 635-640.
207. Bodis S et al. Extensive apoptosis in ductal carcinoma in situ of the breast. Cancer 1996; 77: 1831-1835.
208. Pitot HC et al. Quantitation of multistage carcinogenesis in rat liver. Toxicol Pathol 1996; 24: 119-128.